CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives

SIMPLE SUMMARY: The recent addition of cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (palbociclib, ribociclib, abemaciclib) to endocrine therapy have remarkably improved the outcome of patients with HR+ advanced breast cancer. However, some points of reflections are still undiscussed. To answ...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancers (Basel)
Главные авторы: Roberto, Michela, Astone, Antonio, Botticelli, Andrea, Carbognin, Luisa, Cassano, Alessandra, D’Auria, Giuliana, Fabbri, Agnese, Fabi, Alessandra, Gamucci, Teresa, Krasniqi, Eriseld, Minelli, Mauro, Orlandi, Armando, Pantano, Francesco, Paris, Ida, Pizzuti, Laura, Portarena, Ilaria, Salesi, Nello, Scagnoli, Simone, Scavina, Paola, Tonini, Giuseppe, Vici, Patrizia, Marchetti, Paolo
Формат: Artigo
Язык:Inglês
Опубликовано: MDPI 2021
Предметы:
Review
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7830463/
https://ncbi.nlm.nih.gov/pubmed/33477469
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13020332
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы